1587 related articles for article (PubMed ID: 24009139)
1. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
2. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis.
Watanabe M; Kato J; Inoue I; Yoshimura N; Yoshida T; Mukoubayashi C; Deguchi H; Enomoto S; Ueda K; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Tekeshita T; Mohara O; Ushijima T; Ichinose M
Int J Cancer; 2012 Dec; 131(11):2632-42. PubMed ID: 22383377
[TBL] [Abstract][Full Text] [Related]
3. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer.
Ohata H; Kitauchi S; Yoshimura N; Mugitani K; Iwane M; Nakamura H; Yoshikawa A; Yanaoka K; Arii K; Tamai H; Shimizu Y; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2004 Mar; 109(1):138-43. PubMed ID: 14735480
[TBL] [Abstract][Full Text] [Related]
4. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women: a nested case-control study.
Sasazuki S; Inoue M; Iwasaki M; Otani T; Yamamoto S; Ikeda S; Hanaoka T; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1341-7. PubMed ID: 16835334
[TBL] [Abstract][Full Text] [Related]
5. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels.
Yanaoka K; Oka M; Ohata H; Yoshimura N; Deguchi H; Mukoubayashi C; Enomoto S; Inoue I; Iguchi M; Maekita T; Ueda K; Utsunomiya H; Tamai H; Fujishiro M; Iwane M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2009 Dec; 125(11):2697-703. PubMed ID: 19610064
[TBL] [Abstract][Full Text] [Related]
6. High-Negative Anti-
Inoue M; Sawada N; Goto A; Shimazu T; Yamaji T; Iwasaki M; Tsugane S;
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):420-426. PubMed ID: 31826914
[TBL] [Abstract][Full Text] [Related]
7. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels.
Yanaoka K; Oka M; Yoshimura N; Mukoubayashi C; Enomoto S; Iguchi M; Magari H; Utsunomiya H; Tamai H; Arii K; Yamamichi N; Fujishiro M; Takeshita T; Mohara O; Ichinose M
Int J Cancer; 2008 Aug; 123(4):917-26. PubMed ID: 18508314
[TBL] [Abstract][Full Text] [Related]
8. Relationship between Helicobacter pylori status and serum pepsinogens as serologic markers in atrophic gastritis.
Bölükbaş C; Bölükbaş FF; Ovünç O; Kiliç G; Dalay R; Güven H; Uras F; Yardimci TK; Sökmen MH; Agan AF; Pişkinpaşa N
Turk J Gastroenterol; 2006 Sep; 17(3):172-6. PubMed ID: 16941249
[TBL] [Abstract][Full Text] [Related]
9. Different etiological role of Helicobacter pylori (Hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study using IgG titer against Hp surface antigen.
Tatemichi M; Sasazuki S; Inoue M; Tsugane S;
Acta Oncol; 2008; 47(3):360-5. PubMed ID: 18347999
[TBL] [Abstract][Full Text] [Related]
10. Serological Evaluation of Gastric Cancer Risk Based on Pepsinogen and Helicobacter pylori Antibody: Relationship to Endoscopic Findings.
Kotachi T; Ito M; Yoshihara M; Boda T; Kiso M; Masuda K; Matsuo T; Tanaka S; Chayama K
Digestion; 2017; 95(4):314-318. PubMed ID: 28571035
[TBL] [Abstract][Full Text] [Related]
11. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio--a possible novel and non-invasive marker for gastric atrophy.
Suzuki H; Masaoka T; Hosoda H; Nomura S; Ohara T; Kangawa K; Ishii H; Hibi T
Hepatogastroenterology; 2004; 51(59):1249-54. PubMed ID: 15362725
[TBL] [Abstract][Full Text] [Related]
12. The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and Helicobacter pylori Cag A status.
Yakut M; Örmeci N; Erdal H; Keskin O; Karayel Z; Tutkak H; Soykan I
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):302-11. PubMed ID: 23137754
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis of Helicobacter pylori-induced gastritis by serum pepsinogen levels.
Kitamura Y; Yoshihara M; Ito M; Boda T; Matsuo T; Kotachi T; Tanaka S; Chayama K
J Gastroenterol Hepatol; 2015 Oct; 30(10):1473-7. PubMed ID: 25974661
[TBL] [Abstract][Full Text] [Related]
14. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
15. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany.
Zhang Y; Weck MN; Schöttker B; Rothenbacher D; Brenner H
Cancer Epidemiol Biomarkers Prev; 2013 May; 22(5):821-6. PubMed ID: 23456556
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic findings on serologically defined chronic atrophic gastritis strongly depend on the choice of the cutoff-value.
Brenner H; Rothenbacher D; Weck MN
Int J Cancer; 2007 Dec; 121(12):2782-6. PubMed ID: 17691112
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study.
Kiso M; Yoshihara M; Ito M; Inoue K; Kato K; Nakajima S; Mabe K; Kobayashi M; Uemura N; Yada T; Oka M; Kawai T; Boda T; Kotachi T; Masuda K; Tanaka S; Chayama K
Gastric Cancer; 2017 Sep; 20(5):764-771. PubMed ID: 28025702
[TBL] [Abstract][Full Text] [Related]
18. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
[TBL] [Abstract][Full Text] [Related]
19. Anti-parietal cell antibody and serum pepsinogen assessment in screening for gastric carcinoma.
Sugiu K; Kamada T; Ito M; Kaya S; Tanaka A; Kusunoki H; Hata J; Haruma K
Dig Liver Dis; 2006 May; 38(5):303-7. PubMed ID: 16549394
[TBL] [Abstract][Full Text] [Related]
20. Combining the serum pepsinogen level and Helicobacter pylori antibody test for predicting the histology of gastric neoplasm.
Choi HS; Lee SY; Kim JH; Sung IK; Park HS; Shim CS; Jin CJ
J Dig Dis; 2014 Jun; 15(6):293-8. PubMed ID: 24602176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
